je.st
news
Tag: liver
Merck Announces Presentation of New Findings for ZEPATIER (Elbasvir and Grazoprevir) in Patients with Chronic Hepatitis C at The Liver Meeting
2016-11-12 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced results from multiple analyses at The Liver Meeting 2016, which provide additional evidence supporting the use of ZEPATIER (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C virus (HCV) genotype (GT) 1- or GT4-infected patient populations, including those who receive opioid agonist therapy (OAT), are infected with chronic HCV GT1b, use proton pump inhibitors (PPIs) or have moderate kidney disease.
Tags: the
meeting
presentation
patients
Liverpool's Royal Liver building is put up for sale
2016-10-17 12:46:52| BBC News | Business | UK Edition
Liverpool's Royal Liver building is put up for sale for the first time in its history.
Merck to Present New Data on ZEPATIER (elbasvir and grazoprevir) and Chronic Hepatitis C Clinical Development Programs at The Liver Meeting 2016
2016-10-03 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the companys chronic hepatitis C virus (HCV) clinical development programs will be presented at The Liver Meeting 2016. Fifteen scientific abstracts, including seven oral and eight poster presentations, will highlight findings from Mercks HCV clinical development programs. Language: English Contact: MerckMedia:Doris Li, 908-740-1903Ian McConnell, 908-740-1921orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
data
development
present
Pigs Demonstrate Potential of Gene Therapy for Metabolic Liver Diseases
2016-07-28 02:00:00| ThePigSite - Industry News
US - As part of research to find a new approach to correct metabolic disorders in humans without a whole organ transplant, a study has tested gene therapy in pigs suffering from hereditary tyrosinemia type 1 (HT1), a metabolic disorder caused by an enzyme deficiency.
Tags: potential
therapy
demonstrate
gene
Flummox the liver flukes with timed treatment this fall
2016-04-19 20:54:02| Beef
Many Gulf Coast beef producers treat for liver flukes in the spring when they process their cattle before turnout. read more
Tags: fall
treatment
liver
timed
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »